Avalo Therapeutics, Inc. (AVTX) vs Lexicon Pharmaceuticals, Inc. (LXRX)
Avalo Therapeutics, Inc. and Lexicon Pharmaceuticals, Inc. are both Biotechnology companies. Avalo Therapeutics, Inc. and Lexicon Pharmaceuticals, Inc. are of similar size ($854.3M and $843.1M). Lexicon Pharmaceuticals, Inc. grew revenue faster over the last twelve months: −29.0% against −92.7%. Avalo Therapeutics, Inc. has the higher net margin (0.00% vs −147.4%) and the lower return on invested capital (−118.2% vs −96.4%). Across the 18 metrics below, Lexicon Pharmaceuticals, Inc. leads on 11 and Avalo Therapeutics, Inc. on 7.
Valuation
Profitability
| Metric | AVTX | LXRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 64.72% | 99.14% | 65.16% |
| Operating margin | 0.00% | (131.43%) | 0.00% |
| Net margin | 0.00% | (147.38%) | 0.00% |
| Free cash flow margin | 0.00% | (156.71%) | 0.00% |
| Return on equity | (36.27%) | (40.21%) | (57.72%) |
| Return on assets | (32.50%) | (25.70%) | (49.22%) |
| Return on invested capital | (118.21%) | (96.36%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack